Perugia Consensus Conference on Antiemetic Therapy /
In the last decade, important progress has been achieved in the prevention of chemotherapy-induced nausea and vomiting, in particular since the introduction of 5-HT3 antagonists which, when used in combination with steroids, can assure significant protection in the majority of patients. Nonetheless,...
| Corporate Authors: | , , |
|---|---|
| Other Authors: | , , |
| Format: | Conference Proceeding eBook |
| Language: | English |
| Published: |
Berlin ; New York :
Springer,
[1998]
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Corticosteroids, dopamine antagonists, and other drugs
- Optimal selection of antiemetics in children receiving cancer chemotherapy
- Methodology of antiemetic trials: response assessment, evaluation of new agents, and definition of chemotherapy emetogenicity
- Delayed emesis following anticancer chemotherapy
- Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting
- Consensus proposal for 5-HT₃ antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
- Anticipatory nausea and vomiting in the era fo 5-HT₃ antiemetics.
- Consensus regarding multiple-day and rescue antiemetic therapy
- Etiology and prevention of emesis induced by radiotherapy
- Statistical considerations in the design, conduct, and analysis of antiemetic clinical trials
- Neuropharmacology of emesis and its relevance to antiemetic therapy.